NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/25/2026 14:29
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization483.69 mln
Float10.30 mln
Earnings Date08/10/2026
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-0.94
Highly suspicious
1-Year Forecast
48.31
Transformational upside
Relative Strength
92
/ 100
Top performer
Debt / Equity
-0.20
Negative equity
Dividend Yield
0.00%
No dividend
Business Description
Sutro Biopharma is a California-based biotechnology company focused on developing advanced cancer treatments and vaccines. Its core work centers on a proprietary cell-free protein synthesis technology used to create a new generation of antibody-drug conjugates, which are precision medicines designed to target and destroy cancer cells while minimizing harm to healthy tissue. The company's cancer pipeline targets a range of solid tumors and blood cancers, while its vaccine programs address serious infectious diseases such as pneumococcal illness. Sutro works alongside several major pharmaceutical partners, including Ipsen, Astellas, and Vaxcyte, to bring these therapies to patients around the world.